Clover Health Investments Corp (CLOV)
$1.99
0.03 (1.49%)
CLOV Stock Quote Delayed 30 Minutes
7 Nasdaq Stocks to Sell Before They Die
With more pain ahead for equities, these seven Nasdaq stocks should be the first to be expelled from investors' portfolios.
11 Best Stocks to Buy for 2022
He found Apple at $1.49... Oracle at $0.51... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 11 Stocks for 2022 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
5.76M
Day's Range
$1.98 - $2.10
52-Week Range
$1.95 - $8.58
Dividend & Yield
N/A (N/A)
CLOV Stock Predictions, Articles, and Clover Health Investments Corp News
Clover Health Stock is Cheap, but Still Doesn’t Offer Good Value
Clover Health is moving higher after the company posted strong revenue. But in this case, the price of CLOV stock still doesn't align with its underlying value
Clover Health’s Earnings Losses Make It One to Avoid for Now
CLOV stock should not be bought until it has positive earnings. The company has good growth to report but needs earnings to lower the risk.
CLOV Stock Pops 15% as Hard-Hit Clover Health Grows Revenue
The health insurance company's share price is popping on news of better-than-expected earnings and strong forward guidance.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! We're starting off another busy day of trading with a breakdown of the biggest pre-market stock movers for Tuesday!
All Bets Are Off Whether Clover Health Stock Surges or Sinks From Here
It's not for certain CLOV stock spikes after its upcoming earnings report, and a lot needs to happen for it to make a true price recovery.
Has Clover Health Finally Bottomed Out?
Clover is delivering improved operational results. Management's better than expected guidance lends positive outlook to CLOV stock.
Clover Health’s Technology Is Great But With Dead Money
Clover Health has interesting technology, but unless it can end losses this year it may not have a 2023. It has great technology but may lack the financial strength to make it in the Medicare Advantage arena.
It’s Time for Clover Health to Think Outside the Box
A possible revenue stream for Clover Health is their policyholder’s health data. Could that be a way to get CLOV stock out of its funk?
The Clover Health Debate Will Likely Settle With a Bullish Victory
The Clover Health debate is a fiery one and it won't settle except in hindsight. Meanwhile, the better opportunity in CLOV stock is upside.
Clover Health Stock Is No Longer a Meme Stock
A lack of battleground interest and and Clover Health's improving business bode well for long-term CLOV stock investors.
Don’t Buy CLOV Stock Ahead of Earnings Report
CLOV stock doesn't look good because revenue increases don't trump its greater issues. Don't get in ahead of Q1 earnings.
Clover Health Stock May Rise As Millions Could Lose Health Coverage
CLOV stock has been under heavy selling pressure, but brighter days should lie ahead as Clover Health offers insure-tech solutions.
Do Not Think of Clover Stock as a Bargain Yet
Clover Health certainly has the potential, but it carries more risks. Avoid CLOV stock at the current level.
Clover Stock’s Recovery Could Reverse in the Short-Term
With CLOV stock, a better entry point could emerge between now and its next earnings report.
Clover Health Is Risky But Offers a Healthy Upside Ahead
Clover Health's robust fourth quarter and upbeat guidance has improved the risk/reward opportunity of CLOV stock.
Clover Health Stock’s Outlook Has Improved, but It’s Still a Sell
Clover's profitability metrics are improving but remain dismal, while the firm appears to lack strong, competitive advantages. As a result, CLOV stock is a sell.
Clover Health Is in Need of a Break After Massive Upsurge This Past Month
CLOV stock has seen positive momentum since its earnings release. Due to this, it may become a speculative investment again in the short run.
Clover Health Is in Dire Straits as Medical Costs Remain High
Clover Health’s medical loss ratio remains high. This means that the company is losing money per $1 of revenue it makes. CLOV stock upside could be limited.
Clover Health Stock Will Be Your Lucky Four-Leaf Clover in 2022
CLOV stock is high-risk but potentially also high-reward as Clover Health rakes in the revenue and helps at-risk patients get healthcare.
